Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
in vitro gene mutation study in bacteria
Remarks:
Type of genotoxicity: gene mutation
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
other information
Study period:
Oct 2000
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: well reported GLP guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2000
Report date:
2000

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
Deviations:
yes
Remarks:
no bacteria strain included to detect cross-linking mutagens
GLP compliance:
yes
Type of assay:
bacterial reverse mutation assay

Test material

Constituent 1
Reference substance name:
3 beta,7 alpha,15 alpha-Trihydroxy-5-androsten-17-one
IUPAC Name:
3 beta,7 alpha,15 alpha-Trihydroxy-5-androsten-17-one
Details on test material:
- Name of test material (as cited in study report): ZK 70458
- Batch No.: 87024081

Method

Target gene:
Histidine gene locus
Species / strain
Species / strain / cell type:
other: S. typhimurium TA 1535, TA 100, TA 1537, TA 1538, TA 98
Metabolic activation:
with and without
Metabolic activation system:
liver S9-mix from Aroclor 1254 -treated rats
Test concentrations with justification for top dose:
Dihydroxyprasteron: six to eight concentrations from 0.025 or 0.1 mg, respectively, to 5 mg/plate
Sodium azide: 5 µg/plate (TA 1535 and TA 100 without S9)
2-Nitrofluorene: 10 µg/plate (TA 1538 and TA 98 without S9)
4-Nitro-o-phenylenediamine: 10 µg/plate (TA 1537 without S9)
Benzo[a]pyrene: 2.5 µg/plate (TA 100 and TA 98 with S9)
Cyclophosphamide: 400 µg/plate (TA 1535 with S9)
2-Aminoanthracene: 2.5 µg/plate (with S9)
Controls
Untreated negative controls:
yes
Negative solvent / vehicle controls:
yes
Positive controls:
yes
Positive control substance:
other: Sodium azide (TA 1535 and TA 100), 2-Nitrofluorene (TA 1538 and TA 98), 4-Nitro-o-phenylenediamine (TA 1537), Benzo[a]pyrene (TA 100 and TA 98), Cyclophosphamide (TA 1535), 2-Aminoanthracene

Results and discussion

Test results
Species / strain:
other: Salmonella typhimurium strains TA 1535, TA 100, TA 1537, TA 1538, TA 98
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
other: all strains/cell types tested
Remarks:
Migrated from field 'Test system'.

Any other information on results incl. tables

Precipitates in the agar were found at 0.5 mg/plate.

Applicant's summary and conclusion

Executive summary:

Dihydroxyprasteron was tested in the Salmonella/microsome test for point-mutagenic effects in doses up to 5000 µg/plate on the five histidine-auxotrophic Salmonella typhimurium LT2 strains TA 1535, TA 100, TA 1537, TA 1538 and TA 98.

No cytotoxic effects were seen. Precipitates in the agar were found at 5 mg/plate.

There was no evidence for a mutagenic activity of Dihydroxyprasteron, when tested up to the highest recommended dose level of 5 mg/plate in the absence and presence of S9 mix.